Clinical trials / Minnesota
Psychedelic and ketamine trials recruiting in Minnesota
3 trials registered on ClinicalTrials.gov were recruiting at one or more sites in Minnesota on 26 Oct 2026. By substance: Ketamine / esketamine 2, Psilocybin 1. By condition: depression 2, ptsd 1.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Phase 3Ketamine / esketamineNCT07227454
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (AVENUE)
- Conditions:
- Depressive Disorder, Major
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 12 Years to 17 Years, 258 participants planned
- Also in:
- Brazil, Hungary, Italy, Romania, Spain, Taiwan
- Mayo Clinic, Rochester, Minnesota
Phase 2/3PsilocybinNCT07570654
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder (Redefine)
- Conditions:
- PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms; PTSD, Post Traumatic Stress Disorder
- Sponsor:
- COMPASS Pathways
- Who:
- ages 18 Years and over, 300 participants planned
- Also in:
- Canada
- MN, Eden Prairie, Minnesota
Phase 2Ketamine / esketamineNCT06668571
Intravenous Ketamine for Treatment-Resistant Depression (G2K)
- Conditions:
- Depressive Disorder, Treatment-Resistant; Treatment Resistant Depression (TRD)
- Sponsor:
- Mayo Clinic
- Who:
- ages 18 Years to 65 Years, 30 participants planned
- Mayo Clinic in Rochester, Rochester, Minnesota